The evolving role of interventional cytopathology from thyroid FNA to NGS: Lessons learned at Federico II University of Naples.
FNA
NGS
cytopathology
interventional cytopathology
molecular testing
thyroid
Journal
Cytopathology : official journal of the British Society for Clinical Cytology
ISSN: 1365-2303
Titre abrégé: Cytopathology
Pays: England
ID NLM: 9010345
Informations de publication
Date de publication:
09 Jul 2024
09 Jul 2024
Historique:
revised:
30
05
2024
received:
15
03
2024
accepted:
19
06
2024
medline:
9
7
2024
pubmed:
9
7
2024
entrez:
9
7
2024
Statut:
aheadofprint
Résumé
Fine-needle aspiration (FNA) guided by ultrasound (US) has emerged as a highly precise diagnostic method for managing thyroid nodules, significantly diminishing unnecessary surgeries. The effectiveness of US-guided FNA is high when a single specialist performs the FNA procedure and the microscopy. This paradigm has paved the way for the evolution of interventional cytopathology, a specialist with a pivotal role in the preoperative diagnostic process, encompassing patient history review, clinical examination, FNA execution under US guidance, preparation, and microscopic interpretation of cytological samples. As the landscape of precision medicine unfolds, molecular testing assumes greater importance in thyroid cytopathology, particularly in refining the risk of malignancy for indeterminate nodules. The updated Bethesda classification system underscores the clinical significance of molecular tests, emphasizing their role in refining diagnostic accuracy. With this evolving landscape, interventional cytopathologists must adapt by acquiring expertise in molecular technologies and addressing ongoing challenges in workflow harmonization and optimization. This paper delves into our decade-long experience as interventional cytopathologists, focusing on recent endeavours to ensure adequate samples not only for microscopic diagnosis but also for molecular testing. Additionally, here we review the challenges of integrating next-generation sequencing (NGS) technology into clinical practice, highlighting the importance of integrating clinically meaningful molecular data into comprehensive molecular cytology reports.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
Vohra P, Khanafshar E, Balassanian R. Interventional cytology benefits patients undergoing thyroid FNA. Cancer Cytopathol. 2023;131(4):214‐216.
Wu M. A comparative study of 200 head and neck FNAs performed by a cytopathologist with versus without ultrasound guidance: evidence for improved diagnostic value with ultrasound guidance. Diagn Cytopathol. 2011;39(10):743‐751.
Bellevicine C, Vigliar E, Malapelle U, et al. Cytopathologists can reliably perform ultrasound‐guided thyroid fine needle aspiration: a 1‐year audit on 3715 consecutive cases. Cytopathology. 2016;27(2):115‐121.
Wu M, Choi Y, Zhang Z, et al. Ultrasound guided FNA of thyroid performed by cytopathologists enhances Bethesda diagnostic value. Diagn Cytopathol. 2016;44(10):787‐791.
Pitman MB, Abele J, Ali SZ, et al. Techniques for thyroid FNA: a synopsis of the National Cancer Institute thyroid fine‐needle aspiration state of the science conference. Diagn Cytopathol. 2008;36(6):407‐424.
Linsk JA. Aspiration cytology in Sweden: the Karolinska group. Diagn Cytopathol. 1985;1(4):332‐335.
Grohs HK. The interventional cytopathologist. A new clinician/pathologist hybrid. Am J Clin Pathol. 1988;90(3):351‐354.
Nishino M, VanderLaan P, Troncone G, et al. Molecular and other ancillary tests. In: Ali SZ, VanderLaan PA, eds. The Bethesda System for Reporting Thyroid Cytopathology: definitions, Criteria, and Explanatory Notes. Springer International Publishing; 2023:263‐284.
Cibas ES. We are minimally invasive diagnosis. J Am Soc Cytopathol. 2021;10(2):113‐114.
Abate S, Palombini L, Ferulano GP, Vetrani A, Fresini A, Salvati AM. Our experience in diagnosis of cold nodules of the thyroid by means of thin‐needle biopsy. Minerva Med. 1980;71(23):1633‐1638.
Zajdela A, de Maublanc MA, Schlienger P, Haye C. Cytologic diagnosis of orbital and periorbital palpable tumors using fine‐needle sampling without aspiration. Diagn Cytopathol. 1986;2(1):17‐20.
Romitelli F, Di Stasio E, Santoro C, Iozzino M, Orsini A, Cesareo R. A comparative study of fine needle aspiration and fine needle non‐aspiration biopsy on suspected thyroid nodules. Endocr Pathol. 2009;20(2):108‐113.
Abele JS, Miller TR, King EB, Lowhagen T. Smearing techniques for the concentration of particles from fine needle aspiration biopsy. Diagn Cytopathol. 1985;1(1):59‐65.
Mayall F, Cormack A, Slater S, McAnulty K. The utility of assessing the gross appearances of FNA specimens. Cytopathol off J Br Soc Clin Cytol. 2010;21(6):395‐397.
Tetikkurt US, Oz Puyan F, Oz F, Erdogan N, Ceylan S, Yakupoglu A. Diagnostic value of liquid‐based (Liqui‐PREP) preparations and interobserver reproducibility in fine needle aspiration cytology of the nodular thyroid lesions. Diagn Cytopathol. 2012;40(5):388‐393.
Padmanabhan V, Marshall CB, Akdas Barkan G, et al. Reproducibility of atypia of undetermined significance/follicular lesion of undetermined significance category using the bethesda system for reporting thyroid cytology when reviewing slides from different institutions: a study of interobserver variability: reproducibility of atypia of undetermined significance/follicular lesion. Diagn Cytopathol. 2017;45(5):399‐405.
Kuzan TY, Güzelbey B, Turan Güzel N, Kuzan BN, Çakır MS, Canbey C. Analysis of intra‐observer and inter‐observer variability of pathologists for non‐benign thyroid fine needle aspiration cytology according to Bethesda system categories. Diagn Cytopathol. 2021;49(7):850‐855.
Kocjan G, Chandra A, Cross PA, et al. The interobserver reproducibility of thyroid fine‐needle aspiration using the UK Royal College of Pathologists' classification system. Am J Clin Pathol. 2011;135(6):852‐859.
Crescenzi A, Trimboli P, Basolo F, et al. Exploring the inter‐observer agreement among the members of the Italian consensus for the classification and reporting of thyroid cytology. Endocr Pathol. 2020;31(3):301‐306.
Ali SZ, VanderLaan PA, eds. The Bethesda System for Reporting Thyroid Cytopathology: definitions, Criteria, and Explanatory Notes. Springer International Publishing; 2023.
Salvatore G, Giannini R, Faviana P, et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine‐needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2004;89(10):5175‐5180.
Troncone G, Cozzolino I, Fedele M, Malapelle U, Palombini L. Preparation of thyroid FNA material for routine cytology and BRAF testing: a validation study. Diagn Cytopathol. 2010;38(3):172‐176.
Nishino M. Less is more meets do more with less: exploring differences in thyroid FNA molecular testing between Asian and Western practices. Cancer Cytopathol. 2023;131(7):421‐423.
Bellevicine C, Migliatico I, Sgariglia R, et al. Evaluation of BRAF, RAS, RET/PTC, and PAX8/PPARg alterations in different Bethesda diagnostic categories: a multicentric prospective study on the validity of the 7‐gene panel test in 1172 thyroid FNAs deriving from different hospitals in South Italy. Cancer Cytopathol. 2020;128(2):107‐118.
Nacchio M, Palladino R, Vigliar E, et al. Evaluating local thyroid cytopathology practices by molecular quality metrics: a multi‐institutional study on 4651 FNAs with a focus on the role of the interventional cytopathologist. Cancer Cytopathol. 2023;131(12):772‐780.
Chong Y, Ji SJ, Kang CS, Lee EJ. Can liquid‐based preparation substitute for conventional smear in thyroid fine‐needle aspiration? A systematic review based on meta‐analysis. Endocr Connect. 2017;6(8):817‐829.
Bellevicine C, Sgariglia R, Nacchio M, et al. Molecular testing of thyroid fine‐needle aspiration: local issues and solutions. An interventional Cytopathologist perspective. J Mol Pathol. 2021;2(3):233‐240.
Clark DP. Seize the opportunity: underutilization of fine‐needle aspiration biopsy to inform targeted cancer therapy decisions. Cancer. 2009;117(5):289‐297.
Maxwell P, Salto‐Tellez M. Training in molecular cytopathology testing. Cytopathol Off J Br Soc Clin Cytol. 2018;29(1):5‐9.
De Las Casas LE, Hicks DG. Pathologists at the leading edge of optimizing the tumor tissue journey for diagnostic accuracy and molecular testing. Am J Clin Pathol. 2021;155(6):781‐792.
Ferris RL, Baloch Z, Bernet V, et al. American Thyroid Association statement on surgical application of molecular profiling for thyroid nodules: current impact on perioperative decision making. Thyroid Off J Am Thyroid Assoc. 2015;25(7):760‐768.
Silver Karcioglu A, Iwata AJ, Pusztaszeri M, Abdelhamid Ahmed AH, Randolph GW. The American Thyroid Association (ATA) integrates molecular testing into its framework for managing patients with anaplastic thyroid carcinoma (ATC): update on the 2021 ATA ATC guidelines. Cancer Cytopathol. 2022;130(3):174‐180.
De Luca C, Sgariglia R, Nacchio M, et al. Rapid on‐site molecular evaluation in thyroid cytopathology: a same‐day cytological and molecular diagnosis. Diagn Cytopathol. 2020;48(4):300‐307.
Durante C, Hegedüs L, Czarniecka A, et al. 2023 European Thyroid Association Clinical Practice Guidelines for thyroid nodule management. Eur Thyroid J. 2023;12(5):e230067.
Andrioli M, Carocci S, Alessandrini S, et al. Testing for Afirma in thyroid nodules with high‐risk indeterminate cytology (TIR3B): first Italian experience. Endocr Pathol. 2020;31(1):46‐51.
Aydemirli MD, Snel M, van Wezel T, et al. Yield and costs of molecular diagnostics on thyroid cytology slides in the Netherlands, adapting the Bethesda classification. Endocrinol Diabetes Metab. 2021;4(4):e00293.
Ye W, Hannigan B, Zalles S, et al. Centrifuged supernatants from FNA provide a liquid biopsy option for clinical next‐generation sequencing of thyroid nodules. Cancer Cytopathol. 2019;127(3):146‐160.
Le Mercier M, D'Haene N, De Nève N, et al. Next‐generation sequencing improves the diagnosis of thyroid FNA specimens with indeterminate cytology. Histopathology. 2015;66(2):215‐224.
Song Y, Xu G, Ma T, et al. Utility of a multigene testing for preoperative evaluation of indeterminate thyroid nodules: a prospective blinded single center study in China. Cancer Med. 2020;9(22):8397‐8405.
Sponziello M, Brunelli C, Verrienti A, et al. Performance of a dual‐component molecular assay in cytologically indeterminate thyroid nodules. Endocrine. 2020;68(2):458‐465.
Ren M, Yao Q, Bao L, et al. Diagnostic performance of next‐generation sequencing and genetic profiling in thyroid nodules from a single center in China. Eur Thyroid J. 2022;11(3):e210124.
Zhou Y, Wu X, Zhang Y, et al. Performance of multigene testing in cytologically indeterminate thyroid nodules and molecular risk stratification. PeerJ. 2023;11:e16054.
Bellevicine C, Sgariglia R, Malapelle U, et al. Young investigator challenge: can the ion AmpliSeq cancer hotspot panel v2 be used for next‐generation sequencing of thyroid FNA samples? Cancer Cytopathol. 2016;124(11):776‐784.
Sgariglia R, Nacchio M, Migliatico I, et al. Moving towards a local testing solution for undetermined thyroid fine‐needle aspirates: validation of a novel custom DNA‐based NGS panel. J Clin Pathol. 2022;75(7):465‐471.